AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Knowing when to start saving for retirement is crucial for building a solid financial foundation. Explore the ideal timing for your savings.
25,408 articlesAbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
SpaceX sits on a colossal cash hoard, but does $100 billion guarantee long-term growth? This guide breaks down what t...
Vertex is pursuing Crinetics with a substantial all-cash offer. This deep dive breaks down what the $10 billion bid m...
In 2026, equal-weight XSD and cap-weight SMH offer contrasting bets on AI-driven chipmakers. This article analyzes ho...
Ciena’s shares jumped sharply in the first half of 2026. This article dives into the AI-driven demand for optical net...
When big defense deals surface, Lockheed Martin stock often reacts. This piece breaks down why lockheed martin stock ...
AMD just struck a landmark deal with a global AI cloud leader. This article breaks down what the contract means for r...
When a company's CFO divests shares amid a strong stock run, investors want to know what it means. This deep dive exp...
This in-depth analysis breaks down Celanese’s 2025 earnings trajectory, highlighting drivers, margins, and cash flow....
MakeMyTrip faces a pivotal year as makemytrip (mmyt) 2026 earnings reveal growth amid rising costs. This analysis bre...
A spike in revenue can grab headlines, but it rarely tells the full investment story. Here’s why super micro computer...
AbbVie’s latest clinical progress could shape its dividend future. This guide breaks down what promising results mean...